24/7 Market News Snapshot 14 October, 2025 – Astria Therapeutics, Inc. Common Stock (NASDAQ:ATXS)

October 14, 2025

DENVER, Colo., 14 October, 2025 (www.247marketnews.com) – (NASDAQ:ATXS) are discussed in this article.
Astria Therapeutics, Inc. (ATXS) is currently experiencing a notable surge in market activity, with its stock price reaching $11.987, reflecting a remarkable increase of 41.52% from the previous close of $8.470. This bullish momentum has drawn investor interest, evidenced by a substantial trading volume of 2.08 million shares, suggesting that market sentiment is increasingly optimistic about the company’s future.

This uptrend coincides with BioCryst Pharmaceuticals, Inc.’s recent announcement regarding a strategic acquisition of Astria Therapeutics for an estimated $700 million. The deal involves a mixture of cash and stock that values Astria at $13.00 per share, a significant premium of 53% over its recent closing price. Both companies’ Boards of Directors have unanimously approved the transaction, which is anticipated to close in the first quarter of 2026, pending customary conditions.

The acquisition strategically enhances BioCryst’s offerings, particularly with Astria’s lead product candidate, navenibart, a novel monoclonal antibody designed to provide prophylaxis for hereditary angioedema (HAE). Navenibart is distinguished by its long-acting dosing schedule, positioning it as a best-in-class therapy that seeks to fulfill unmet needs within the HAE patient community. Given BioCryst’s established infrastructure and expertise in the rare disease market, the company is poised to maximize patient access to this innovative treatment.

Dr. Jill C. Milne, CEO of Astria, is expected to join the BioCryst Board upon completion of the acquisition. This collaboration signifies a joint commitment to leveraging expertise for patient benefit. Jon Stonehouse, CEO of BioCryst, emphasized the importance of navenibart in their portfolio, stating that the acquisition aligns with their goal of providing transformative solutions for patients facing the challenges of rare diseases. The transaction is set to reinforce BioCryst’s position in the market while paving the way for future growth and advancements in patient care.

Related news for (ATXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.